Article Text

SP0005 Co-Morbidity in Psoriatic Arthritis? Beyond the Skin and Joints
  1. H. Marzo-Ortega
  1. Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Disease, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom


Psoriatic arthritis (PsA) is a common inflammatory disorder affecting 0.3-1% of the general population, and can be found in 10-40% of the psoriasis (Pso) population. The physical and psychological burden of the musculoskeletal and skin symptoms in affected individuals is substantial, leading to a significant impact on their quality of life. Recent epidemiological studies have shown that beside the joint and skin involvement, PsA and Pso may be associated to multiple systemic comorbidities including metabolic syndrome, other autoimmune diseases and lymphoma. Further, the higher prevalence of metabolic syndrome together with the inflammatory burden associated to both PsA and Pso contribute to an increased cardiovascular risk and mortality. The complexity of this “psoriatic disease” suggests that management should not only be targeted at the skin and joints but should encompass an individualized holistic approach to address by-standing co-morbidities and lifestyle adjustments.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.